This is the second manufacturing facility in the region for ACG Group, including the previously acquired Nova Nordeplast plant in Sao Paulo, Brazil, it acquired in 2017. The capsules facility was an R$350m (US$98m) investment by the company and will serve the Latin American market.
Selwyn Noronha, CEO of ACG Capsules, said in a statement that the capsule manufacturing company “already has a significant presence in LATAM, and following this investment, [it] will further be able to meet the growing requirements of the region.”
With the capsule manufacturing plant in Pouso Alegre, Brazil, the company will see the addition of 500 new local employees. The site has met the standards defined by the Brazilian Health Regulatory Agency (ANVISA) and Good Manufacturing Practice (GMP) authorities.
Brazil is a strategic commitment for ACG as it is the fifth largest pharmaceutical market in the world, according to Roberson Petrungaro, commercial director, ACG Capsules LATAM.
Both the Sao Paulo facility and the capsule plant will offer differentiated solutions, including printing on hard capsules.
Beyond printing, ACG added Applied DNA Sciences’ molecular tagging and authentication technology to its capsule products in March 2018 to prevent falsified and counterfeit medicines – it will bring this technology to its newest manufacturing site.
